In this paper, we decided to reanalyse the data using the different validated methods of risk expression. Using main publications, absolute risks (AR), AR reduction (ARR), number needed to treat (NNT) were calculated for five COVID-19 vaccines (tozinameran Comirnaty, Moderna, Vaxzevria, ...
We estimated the average protection against both symptomatic and severe COVID-19 provided by the different boosters over a 6-month period, assuming antibody titers decay at the same rate for both vaccines (with a half-life of 108 days15,17,19). The relative benefits of a variant-modified...
HLB said it has verified the safety and protection of the Covid-19 vaccine, Nanocovax, developed by Vietnam-based pharmaceutical company, Nanogen. HLB said it has verified the safety and protective efficacy of the Covid-19 vaccine, Nanocovax, developed by Vietnam-based pharmaceutical company Na...
This systematic review and meta-analysis evaluates the efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years.
It is widely accepted that multiple effective COVID-19 vaccines will be required to control the pandemic. The pace of COVID-19 vaccine development has been unprecedented[1]; there are >140 candidates in development, representing a wide range of platforms and strategies. Importantly, however, the...
Severe acute respiratory syndrome coronavirus 2 had devastating consequences for human health. Despite the introduction of several vaccines, COVID-19 continues to pose a serious health risk due to emerging variants of concern. DNA vaccines gained importa
Prevention of infection through public vaccination would be the only efficient strategy to control the morbidity and mortality caused by COVID-19. To date, several COVID-19 vaccines using different platforms including nucleic acid-based vaccines, adenovirus-based vaccines, protein-based vaccines, and ...
Novavax expects that, if approved in South Africa, its COVID-19 vaccine would ultimately be supplied to South Africa through Novavax’ recently announced collaboration with the Serum Institute of India. “The major motivation for the COVID-19 vaccines being evaluated at an early stage in South...
There is virtually no protection against infection with the currently circulating omicron variant of the SARS-CoV-2 virus for dual-vaccinated and recovered individuals who were infected with the previous SARS-CoV-2 variants. Only individuals who have been immunized against COVID-19 with a third vac...
Collaboration and standardised approaches for assessing different vaccine efficacy endpoints are key for meaningful comparison of different COVID-19 vaccine candidates to ensure that the most effective vaccines are deployed, say authors of an opinion pie